RT Journal Article
SR Electronic
T1 Human papillomavirus testing as an optional screening tool in low-resource settings of Latin America: experience from the Latin American Screening study
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP 955
OP 962
DO 10.1136/ijgc-00009577-200605000-00001
VO 16
IS 3
A1 A. Longatto-Filho
A1 M. Eržen
A1 M. Branca
A1 C. Roteli-Martins
A1 P. Naud
A1 S. F.M. Derchain
A1 L. Hammes
A1 L. O. Sarian
A1 J. F. Bragança
A1 J. Matos
A1 R. Gontijo
A1 T. Lima
A1 M. Y.S. Maeda
A1 S. Tatti
A1 S. Syrjänen
A1 G. Dores
A1 A. LÖRINCZ
A1 K. Syrjänen
YR 2006
UL http://ijgc.bmj.com/content/16/3/955.abstract
AB Hybrid capture II (HC II) test for oncogenic human papillomaviruses (HPV) was carried out in a cohort of 4284 women at their first clinical visit. Overall prevalence of HPV was 17.1%, decreasing with age from 33.9% among women below 20 years to only 11.0% among those older than 41 years. HPV prevalence was significantly higher among current smokers (odds ratio [OR] = 1.31; 95% CI 1.1–1.6), in women with two or more lifetime sexual partners (OR = 1.9; 95% CI 1.6–2.4), and those women with two or more sexual partners during the past 12 months prior to examination (OR = 1.6; 95% CI 1.2–2.2). HPV detection increased in parallel with increasing cytologic abnormality, being highest in women with high-grade squamous intraepithelial lesion (P = 0.001). Specificity of the HPV test in detecting histologically confirmed cervical disease was 85% (95% CI 83.9–86.1). Sensitivity of the HPV test in detecting histologic abnormalities increased in parallel with disease severity, ranging from 51.5% for cervical intraepithelial neoplasia (CIN) 1 to 96.5% for CIN 3 and 100.0% for cancer, with respective decline of positive predictive value. These data suggest that HPV testing with HC II assay might be a viable screening tool among this population with relatively high prevalence of cervical disease.